Innocoll Holdings plc to Present at the Morgan Stanley Global Healthcare Conference
September 07 2016 - 4:01PM
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty
pharmaceutical and medical device company with late stage
development programs targeting areas of significant unmet medical
need, today announced that Anthony Zook, Chief Executive Officer of
Innocoll Holdings plc, will participate in a fireside chat at the
Morgan Stanley Global Healthcare Conference on Tuesday, September
13, 2016, at 11:10 a.m. ET at the Grand Hyatt Hotel in New York,
NY.
About Innocoll Holdings plc
Innocoll is a global, specialty pharmaceutical company with late
stage development programs that is dedicated to engineering better
medicines to help patients get better. Our proprietary,
biocompatible, and biodegradable collagen products are
precision-engineered for targeted use. Applied locally to wound
and/or surgery sites, they are designed to provide a range of
benefits. The company's late stage product pipeline is focused on
addressing a number of large unmet medical needs, including:
XARACOLL for the treatment of postoperative pain; COGENZIA
(INL-002), a gentamicin-collagen topical matrix for the adjuvant
treatment of diabetic foot infections; and COLLAGUARD (INL-003), a
barrier for the prevention of post-surgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US),
COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and
ZORPREVA®.
Corporate:
Pepe Carmona
Chief Financial Officer
(215) 983-3362
pcarmona@innocoll.com
Jeannie Sorenson, M.D.
Vice President, Investor Relations
(314) 458-7355
jsorenson@innocoll.com
Innocoll AG (NASDAQ:INNL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innocoll AG (NASDAQ:INNL)
Historical Stock Chart
From Sep 2023 to Sep 2024